Meyer J S, Province M A
St. Luke's Hospital, Chesterfield, Missouri 63017.
Cancer. 1994 Oct 15;74(8):2287-99. doi: 10.1002/1097-0142(19941015)74:8<2287::aid-cncr2820740813>3.0.co;2-y.
S-phase fraction (SPF) predicts the prognosis of patients with breast cancer independently of tumor size, axillary metastasis, estrogen receptor (ER) and progesterone receptor (PgR), and patient age. Whether SPF is best measured by DNA labeling index (SPF-LI) or by flow cytometry (SPF-Flow) and what is the relative efficacy of SPF versus histopathologic characteristics for prognosis have remained unanswered questions.
The authors studied 845 women with Stages I-II disease classification for years 1975-1990 with end results data, who were treated surgically with axillary lymph node dissection by an in vitro DNA labeling index protocol with tritiated thymidine or 5-bromo-2'-deoxyuridine and whose SPF was measured microscopically. Nuclear size was estimated with a calibrated optical grid as less than 11 microns, 11-14 microns, or greater than 14 microns. DNA flow cytometry was performed on fresh or paraffin embedded tissue; ER and PgR were performed by cytosol assay. Kaplan-Meier survival plots and multivariate analysis were used for comparisons.
Tumor size, axillary lymph nodal status, SPF-LI, nuclear size, and ER all related strongly to breast cancer specific survival and relapse free survival. PgR was less effective. Lymph node status and tumor size predicted long term survival; differences for other variables largely disappeared by 10 years. By multivariate analysis, axillary lymph node status, tumor size, and ER were independently prognostic for disease specific, relapse free survival. A strong trend was found for nuclear size. PgR, DNA ploidy, and SPF did not contribute to prognosis independently. Nuclear size was the strongest independent predictor in patients with negative axillary lymph nodes.
The number of positive axillary lymph nodes, tumor size, ER, and nuclear size were the strongest predictors of prognosis for patients with breast cancer. Only tumor size and lymph node status predicted the long term risk of metastasis.
S期细胞分数(SPF)可独立于肿瘤大小、腋窝转移、雌激素受体(ER)、孕激素受体(PgR)及患者年龄来预测乳腺癌患者的预后。SPF究竟是通过DNA标记指数(SPF-LI)还是流式细胞术(SPF-Flow)来最佳测定,以及SPF相对于组织病理学特征对预后的相对效能如何,这些问题仍未得到解答。
作者研究了1975年至1990年间845例患有I-II期疾病的女性,这些女性有最终结果数据,她们通过体外DNA标记指数方案,用氚标记胸腺嘧啶或5-溴-2'-脱氧尿苷进行腋窝淋巴结清扫术治疗,且其SPF通过显微镜测量。用校准的光学网格估计核大小小于11微米、11 - 14微米或大于14微米。对新鲜或石蜡包埋组织进行DNA流式细胞术检测;通过胞质溶胶测定法检测ER和PgR。采用Kaplan-Meier生存曲线和多变量分析进行比较。
肿瘤大小、腋窝淋巴结状态、SPF-LI、核大小和ER均与乳腺癌特异性生存和无复发生存密切相关。PgR的作用较小。淋巴结状态和肿瘤大小可预测长期生存;其他变量的差异在10年后基本消失。通过多变量分析,腋窝淋巴结状态、肿瘤大小和ER对疾病特异性、无复发生存具有独立预后价值。发现核大小有很强的趋势。PgR、DNA倍体和SPF对预后无独立贡献。核大小是腋窝淋巴结阴性患者中最强的独立预测因子。
腋窝淋巴结阳性数目、肿瘤大小、ER和核大小是乳腺癌患者预后的最强预测因子。只有肿瘤大小和淋巴结状态可预测转移的长期风险。